BRAF V600K + LDH-H
|
Melanoma
|
BRAF V600K + LDH-H
|
Melanoma
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
BRAF V600K + LDH-H
|
Melanoma
|
BRAF V600K + LDH-H
|
Melanoma
|
BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
|
BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
|
BRAF V600K + LDH-H
|
Melanoma
|
BRAF V600K + LDH-H
|
Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|